In another pathological setting, Wang et al. reported that PARP1/ARTD1 and PARP2/ARTD2 inhibition with olaparib [24,25,26,27] (a PARP1/ARTD1/2 inhibitor approved by the Food and Drug Administration for the treatment of ovarian, breast, pancreatic, and prostate cancer) induced macrophage reprogramming towards an anti-tumor, pro-inflammatory phenotype [28]. Here, PARP2 is linked to Familial prostate cancer.